Feasibility and Safety of Split‐Liver Transplantation in a Nascent Framework of Deceased Donation

Ramkiran Cherukuru, Mettu Srinivas Reddy, Naresh P. Shanmugam, Rajesh Rajalingam, Venugopal Kota, Vasanthakumar Gunasekaran, Gomathy Narasimhan, Ilankumaran Kaliamoorthy, Mohamed Rela – 26 December 2018 – Split‐liver transplantation (SLT) is a valuable option for optimizing the use of good‐quality deceased donor grafts. It is not routinely reported outside the West because of limited deceased donor numbers, technical and organizational constraints, lack of experience, and a predominant living donor liver transplantation (LDLT) practice.

Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Fasiha Kanwal, Elliot B. Tapper, Chanda Ho, Sumeet K. Asrani, Nadia Ovchinsky, John Poterucha, Avegail Flores, Victor Ankoma‐Sey, Bruce Luxon, Michael Volk – 26 December 2018 – Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis.

Pevonedistat, a Neuronal Precursor Cell‐Expressed Developmentally Down‐Regulated Protein 8–Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus

Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Mari Yamagami, Takahiro Kishikawa, Takahiro Seimiya, Tatsunori Suzuki, Eri Tanaka, Rei Ishibashi, Kazuyoshi Funato, Kazuhiko Koike – 26 December 2018 – Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV‐related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented.

Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Fasiha Kanwal, Elliot B. Tapper, Chanda Ho, Sumeet K. Asrani, Nadia Ovchinsky, John Poterucha, Avegail Flores, Victor Ankoma‐Sey, Bruce Luxon, Michael Volk – 26 December 2018 – Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis.

Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation

Austin Moore, Linwei Wu, Jen‐Chieh Chuang, Xuxu Sun, Xin Luo, Purva Gopal, Lin Li, Cemre Celen, Michael Zimmer, Hao Zhu – 25 December 2018 – Nonalcoholic steatohepatitis (NASH) is a rapidly growing cause of chronic liver damage, cirrhosis, and hepatocellular carcinoma. How fatty liver pathogenesis is subject to epigenetic regulation is unknown. We hypothesized that chromatin remodeling is important for the pathogenesis of fatty liver disease.

Dual‐Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta–Activated Kinase 1 Suppression

Ping Ye, Jijun Liu, Wuping Xu, Denghai Liu, Xiangchao Ding, Sheng Le, Hao Zhang, Shanshan Chen, Manhua Chen, Jiahong Xia – 24 December 2018 – Nonalcoholic fatty liver disease (NAFLD), which has a wide global distribution, includes different stages ranging from simple steatosis to nonalcoholic steatohepatitis, advanced fibrosis, and liver cirrhosis according to the degree of severity. Chronic low‐grade inflammation, insulin resistance, and lipid accumulation are the leading causes of NAFLD. To date, no effective medicine for NAFLD has been approved by governmental agencies.

Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program

Monica A. Konerman, Aashesh Verma, Betty Zhao, Amit G. Singal, Anna S. Lok, Neehar D. Parikh – 24 December 2018 – There are limited data on the downstream effects of hepatocellular carcinoma (HCC) surveillance, including the frequency of false‐positive results. We aimed to quantify the incidence of indeterminate nodules (INs) and the follow‐up testing needed to resolve these findings among patients enrolled in a structured HCC surveillance program. We retrospectively analyzed adult patients with cirrhosis enrolled in a structured HCC surveillance program in a large tertiary care center.

Subscribe to